[Ebastine : treatment of perennial rhinitis in the child].
Ebastine is H1 receptor antagonist, powerful and selective for histamine. Its efficacy has been evaluated in control of symptoms of persistent rhinitis, appearance of secondary effects and tolerance of the drug, in 30 children who were suffering from persistent rhinitis, of which the diagnosis included:- clinical history, skin tests (prick test) nasal and conjunctival provocation tests, total and specific IgE. All the children had treatment for 30 days. The parameters followed were:- clinical score, skin tests, nasal and conjunctival provocations and evaluation of secondary effects, of the start and 10 days after the end of treatment. The results obtained were a disappearance or reduction of the weals from histamine and specific antigens, disappearance or reduction of the response in nasal and conjunctival provocation with carbachol or specific antigens, clear clinical improvement in 22 patients, in 2 small improvement and no response in 6 patients. We conclude that Ebastine improved the clinical symptoms in persistent rhinitis, the skin test is inhibited and sensitivity of the shock organ is reduced. No secondary effects were seen on the Central Nervous System (SNC) and the tolerance of the drug was very good.
Benavente
V
V
Service d'allergie et immunologie clinique pédiatrique, hôpital universitaire materno-infantile, Vall d'Hebron, Barcelone.
Eseverri
J L
JL
Botey
J
J
Marin
A
A
D000293:Adolescent; D002090:Butyrophenones / Q000627:therapeutic use*; D002217:Carbachol; D002648:Child; D003233:Conjunctivitis, Allergic / Q000188:drug therapy; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009299:Nasal Provocation Tests; D010880:Piperidines / Q000627:therapeutic use*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D012882:Skin Tests; D016896:Treatment Outcome
D002090:Butyrophenones; D006634:Histamine H1 Antagonists; D010880:Piperidines; D002217:Carbachol; C058249:ebastine